EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19

GÁZQUEZ-PÉREZ, R.¹, SÁNCHEZ-RODRÍGUEZ, B.¹, GÓMEZ-SÁNCHEZ, MT.¹, GÁMEZ TORRES, D.¹, SÁNCHEZ-VARELA, M.¹, MORENO-DÍAZ, T.¹
¹H.U TORRECÁRDENAS, PHARMACY, ALMERIA, SPAIN.

BACKGROUND AND IMPORTANCE
Cilgavimab/tixagevimab are two recombinant human IgG1κ monoclonal antibodies indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents ≥12 years old weighing ≥40 kg. In Spain, potential candidates are people with high degree of immunosuppression (due to pathology or treatment), who do not respond adequately to vaccination (anti-anati-S antibodies <260 BAU/ml).

AIM AND OBJECTIVES
To analyze the effectiveness and safety of cilgavimab/tixagevimab in a tertiary care hospital

MATERIALS AND METHODS
Descriptive, observational, retrospective study.

RESULTS

CONCLUSION AND RELEVANCE
The treatment was effective in the majority of patients in our hospital
This supports the use of the drug as prophylaxis to prevent COVID-19 in people who do not respond sufficiently to vaccination
The treatment was well tolerated, presenting low incidence of adverse reactions. Longer term studies should be performed